Drugs / dendritic cell-gp100-MART-1 antigen vaccine
dendritic cell-gp100-MART-1 antigen vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004025 | Mar 1999 → ? | cutaneous melanoma | Genzyme, a Sanofi Company | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00019890 | ? → Mar 2007 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dendritic cell-gp100-MART-1 antigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019890 ↗ |
| Modality | Vaccine | “Vaccine Therapy” NCT00004025 ↗ |
| Route | Subcutaneous | “modified autologous dendritic cells subcutaneously” NCT00004025 ↗ |